Phase 2Completed
Low-dose Naltrexone for Post-COVID Fatigue Syndrome
A Double Blind Randomized Trial of Low-dose Naltrexone for Post-COVID Fatigue Syndrome
- Sponsor
- Luis Nacul (Academic or other)
- Enrollment
- 160 enrolled
- Conditions
- Post-Viral Fatigue Syndrome
- Interventions
- Low-Dose Naltrexone; Placebo
- Ages
- adults, older adults
- Registry
- NCT05430152
Full record on ClinicalTrials.gov
From the registry
This study aims to determine if low-dose naltrexone (LDN) reduces fatigue, improves related symptoms, and reduces inflammatory markers in peripheral blood in cases with Post-COVID-19 Fatigue Syndrome (PCFS) from COVID-19 (i.e. confirmed SARS-CoV-2 case). LDN refers to naltrexone given in doses of 1-4.5 mg. Overall, studies have found that LDN is safe and well-tolerated. It may help to reduce pain and inflammation and improve well-being and immune function.The trial will be conducted by the Complex Chronic Diseases Program (CCDP) at BC Women's Hospital and will demonstrate whether LDN could benefit a large number of people with PCFS.
Primary outcomes
- Fatigue Intensity
History
Last registry update
Study completion
Primary completion
Started
Registered